Eli Lilly And Company (LLY): Today's Featured Drugs Loser
(
) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day down 2.6%. By the end of trading, Eli Lilly and Company fell 49 cents (-1.4%) to $35.65 on light volume. Throughout the day, 3.8 million shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 8.5 million shares. The stock ranged in price between $35.62-$35.96 after having opened the day at $35.83 as compared to the previous trading day's close of $36.14. Other company's within the Drugs industry that declined today were:
(
), down 43.3%,
Rosetta Genomics
(
ROSGD
), down 43.3%,
Accelr8 Technology Corporation
(
), down 16.4%, and
Bacterin International Holdings Inc
(
), down 14.7%.
Eli Lilly and Company develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $42.07 billion and is part of the
sector. The company has a P/E ratio of 8.7, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7. Shares are up 3.1% year to date as of the close of trading on Tuesday.
TheStreet Ratings rates Eli Lilly and as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.
- You can view the full Eli Lilly and Ratings Report.
On the positive front,
(
), up 11%,
(
), up 9.6%,
(
), up 9.2%, and
(
), up 7%, were all gainers within the drugs industry with
(
) being today's featured drugs industry winner.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
- Find other investment ideas from our top rated ETFs lists.
null
